Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

Blood (2016) 128 (24): 2819–2823.

https://doi.org/10.1182/blood-2016-05-713099

Published: 2016

Includes: Supplemental data

Journal Articles

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

Brian Philip, Evangelia Kokalaki, Leila Mekkaoui, Simon Thomas, Karin Straathof, Barry Flutter, Virna Marin, Teresa Marafioti, Ronjon Chakraverty, David Linch, Sergio A. Quezada, Karl S. Peggs, Martin Pule

Blood (2014) 124 (8): 1277–1287.

https://doi.org/10.1182/blood-2014-01-545020

Published: 2014

Includes: Supplemental data

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Mary Gleeson, FRCPath, Wendi Qian, PhD, David Cunningham, FMedSci, Eliza Hawkes, FRACP, Andrew Jack, PhD, Paul Smith, MSc, Paul Mouncey, MSc, Christopher Pocock, PhD, Kirit M Ardeshna, FRCPath, John Radford, MD, Andrew McMillan, FRCPath, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter Johnson, FRCP, Joanna Gambell, BSc, David Linch, FMedSci

Blood (2013) 122 (21): 4268.

https://doi.org/10.1182/blood.V122.21.4268.4268

Published: 2013

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

Eric Van Den Neste, MD, PhD, Christian Gisselbrecht, MD, Norbert Schmitz, Nicolas Mounier, MD, PhD, Devinder S Gill, David Linch FMedSci, Marek Trneny, MD, Ph.D.,, Noel Milpied, MD, PhD, John Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, MPH, Ulrich Dührsen, MD, David Ma, MD, Josette Brière, MD, Catherine Thieblemont, MD, PhD, Gilles Andre Salles, MD, PhD, Craig H. Moskowitz, MD, Bertram Glass

Blood (2013) 122 (21): 764.

https://doi.org/10.1182/blood.V122.21.764.764

Published: 2013

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Noha Chowdhry, Stephanie Verfuerth, PhD, Panos Kottaridis, Anthony H. Goldstone, FRCP, FRCPath, Kirit Ardeshna, MD, David Linch, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD

Blood (2009) 114 (22): 200.

https://doi.org/10.1182/blood.V114.22.200.200

Published: 2009

Journal Articles

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Marc R Mansour, MBChB, MRCP, Rosemary Gale, PhD, Asim Khwaja, Martin Pule, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP, David Linch

Blood (2008) 112 (11): 3364.

https://doi.org/10.1182/blood.V112.11.3364.3364

Published: 2008

Journal Articles

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

John Radford, Michael O’Doherty, Sally Barrington, Wendi Qian, Philippa Patrick, Stewart Coltart, Dominic Culligan, Jennie Wimperis, Eric Bessell, David Linch, Peter Johnson, David Cunningham, T. Andrew Lister, Peter Hoskin, Ruth Pettengell, Barry Hancock, Timothy Illidge

Blood (2008) 112 (11): 369.

https://doi.org/10.1182/blood.V112.11.369.369

Published: 2008

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis.

Charalampia Kyriakou, MD, Ayoma Attygalle, MD, David Linch, MD, PhD, Anthony Goldstone, MD, Paul Smith, Ahmet Dogan, MD, PhD

Blood (2005) 106 (11): 2810.

https://doi.org/10.1182/blood.V106.11.2810.2810

Published: 2005

Journal Articles

Favourable Prognosis Associated with FLT3 Tyrosine Kinase Domain Mutations in AML in Contrast to the Adverse Outcome Associated with Internal Tandem Duplications.

Adam Mead, David Linch, Robert Hills, Keith Wheatley, Alan Burnett, Rosemary Gale

Blood (2005) 106 (11): 334.

https://doi.org/10.1182/blood.V106.11.334.334

Published: 2005

Journal Articles

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Murray Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl Peggs, David Linch, Anthony Goldstone, Stephen Mackinnon

Blood (2004) 104 (13): 3865–3871.

https://doi.org/10.1182/blood-2004-03-1105

Published: 2004

Journal Articles

Is more better?

David Linch

Blood (2004) 104 (3): 596–597.

https://doi.org/10.1182/blood-2004-05-1823

Published: 2004

Journal Articles

Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia

Björn Andréasson, Claire Harrison, Göran Lindstedt, David Linch, Jack Kutti

Blood (2003) 101 (2): 783.

https://doi.org/10.1182/blood-2002-06-1909

Published: 2003

Journal Articles

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

Paul N. Mainwaring, David Cunningham, Walter Gregory, Peter Hoskin, Barry Hancock, Andrew J. Norton, Ken MacLennan, Paul Smith, Gillian Vaughan Hudson, David Linch

Blood (2001) 97 (10): 2991–2997.

https://doi.org/10.1182/blood.V97.10.2991

Published: 2001

NARROW

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis.

Favourable Prognosis Associated with FLT3 Tyrosine Kinase Domain Mutations in AML in Contrast to the Adverse Outcome Associated with Internal Tandem Duplications.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Is more better?

Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only